9月16日，上海昊海生物科技股份有限公司（简称"昊海生科"）发布公告称，公司控股股东、实际控制 人之一蒋伟于2025年5月收到中国证监会出具的《立案告知书》，因其涉嫌内幕交易，中国证监会决定 对其立案。近日，公司收到蒋伟通知，获悉其收到中国证监会出具的《行政处罚事先告知书》。尽管昊 海生科多次强调该事件为个人行为与公司无关，但实控人被罚风波仍引发了投资者对公司发展的担忧。 公司回应实控人被罚：与公司无关 关于此次实控人被罚事件，昊海生科在公告中表示，该《行政处罚事先告知书》所涉主体为蒋伟个人， 涉及的事项与公司无关。蒋伟不参与公司日常经营管理，该事项不会对公司日常经营、业务及财务造成 重大影响。 其实，今年5月7日，昊海生科就曾发布公告称，公司收到控股股东、实际控制人之一蒋伟通知，其收到 中国证监会出具的《立案告知书》，因涉嫌内幕交易，根据《中华人民共和国证券法》《中华人民共和 国行政处罚法》等法律法规，决定对其立案。 作为昊海生科的创始人之一，2007年，蒋伟创立了昊海生科的前身昊海有限，成立之初，昊海有限并未 开展实际生产经营活动，后续，凭借一系列精准的并购等资本运作手段切入医美赛道，并逐步在行业内 站稳 ...

Group 1 - The core issue revolves around the investigation of the controlling shareholder, Jiang Wei, for insider trading, which has raised concerns about potential related party transactions and market trust in the company [1][2] - The company reported a significant decline in revenue growth, with a 1.64% increase projected for 2024, marking a four-year low, while traditional business segments are experiencing revenue declines [2][3] - The company's reliance on acquisitions for growth is being questioned, as the integration of acquired entities has shown mixed results, and R&D investment has decreased significantly [3][4] Group 2 - The company faces internal challenges, including governance issues and declining performance, while external pressures from industry competition and pricing strategies are intensifying [4] - The medical aesthetics sector is becoming increasingly competitive, with other players also facing challenges, indicating a potential end to the high-growth phase for hyaluronic acid products [3][4] - To regain market confidence, the company must address compliance, innovate in R&D, and diversify its business operations [4]

Core Viewpoint - The company, Haohai Biological Technology, is facing scrutiny as its controlling shareholder, Jiang Wei, has been notified of an investigation by the China Securities Regulatory Commission (CSRC) for suspected insider trading, although the company asserts that this matter is unrelated to its operations [1][3]. Company Overview - Haohai Biological Technology is engaged in the research, production, and sales of medical devices and pharmaceuticals, focusing on four main areas: medical aesthetics and wound care products, ophthalmic products, orthopedic viscoelastic supplements, and anti-adhesion and hemostatic products [3]. Financial Performance - In 2024, the company reported revenues of approximately 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit attributable to shareholders of about 420 million yuan, up 1.04% [5]. - The company's overall gross margin decreased from 70.46% to 69.89% due to significant price reductions in certain products, which offset the growth in high-margin medical aesthetic products [5]. - The medical aesthetics and wound care segment contributed over 40% of the company's revenue, with a year-on-year increase of 13.08%, although this growth rate has slowed compared to the previous year's 41.27% [5][6]. Market Reaction - Following the announcement of the investigation, Haohai Biological Technology's stock opened down 4.31% on May 8, with a closing price of 52.26 yuan per share, reflecting a decline of 1.71% and a total market capitalization of 12.19 billion yuan [4]. - The company's stock has seen a cumulative decline of 71.76% from its peak in July 2021, and the current share price has fallen below its initial public offering price of 89.23 yuan [7]. Future Outlook - The company plans to continue utilizing its own funds to explore advancements in the medical aesthetics, ophthalmology, orthopedics, and surgical fields, seeking to enhance its product portfolio through technology introduction or investment partnerships [7].

Group 1 - The core issue involves the investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading [1] - The investigation pertains solely to Jiang Wei as an individual and does not involve the company's stock or daily operations, indicating no significant impact on the company's regular business activities [2] Group 2 - On May 7, Haohai Biological Technology's stock closed at 53.17 yuan per share, down 0.21%, with a market capitalization of 12.4 billion yuan [3] - The company recently announced a stock buyback, having repurchased approximately 1.49 million A-shares, accounting for 0.64% of the total share capital, with a total transaction amount of about 85.94 million yuan [3] - For the fiscal year 2024, Haohai Biological Technology reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, a year-on-year increase of 1.04%, indicating stagnation in growth [3] - The overall gross margin decreased from 70.46% to 69.89%, despite the increasing revenue share from high-margin hyaluronic acid products, due to significant price declines in other products [3] Group 3 - In Q1 2025, Haohai Biological Technology reported total revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.31 million yuan, down 7.41% [4] - The decline in performance reflects intense competition in the hyaluronic acid and medical aesthetics market, with emerging alternative materials reshaping the landscape [4] - Research indicates that recombinant collagen may replicate the success of hyaluronic acid, supported by continuous improvements in supply chain policies and technological breakthroughs [4]